Abstract
Inclisiran access requires operational infrastructure beyond convenient dosing. ORION-10 and ORION-11 trials (1,561 and 1,617 participants) demonstrated LDL-C lowering; FDA approved inclisiran in December 2021 on this evidence. The drug's label specifies initial dose at month zero, repeat at month three, then every six months thereafter, requiring healthcare professional administration. A fictional clinic receiving 1,000 referrals over six months faces sequential handoffs: clinical assessment, coverage verification, appointment scheduling, and visit completion. Baseline workflow completion rates (80%, 75%, 80%, 90% respectively) yield approximately 432 expected initial visits; improving all four steps to 90%, 85%, 90%, 95% produces roughly 654 expected starts—a gain of 222 patients. However, this assumes downstream capacity exists; fixed appointment slots may simply shift queues. Starter cohorts demand distinct capacity planning: 432 baseline starters require 1,296 first-year administrations; 654 improved starters require 1,962 administrations. A 2,400-slot annual clinic cannot assume both new and maintenance visits fit without clustering effects, cancellations, and staff absence. A hypothetical $45,000 coordination project yields $39,973.50 additional contribution at $60 per completed administration across three incremental visits—insufficient recovery without explicit broader service goals. Financial modeling must account for inventory purchase timing versus payment collection to avoid funding gaps. Clinics should establish baseline referral resolution metrics, distinguish patient choice from operational failure, and observe actual queue constraints before expanding capacity. This analysis separates observed evidence (trial endpoints, label specifications) from operational scenarios and financial assumptions, all hypothetical.
Read the complete research: Inclisiran access: the referral queue behind an infrequent injection.